Schriefer D, Haase R, Ness N-H, Ziemssen T. Cost of illness in multiple sclerosis by disease characteristics–A review of reviews. Expert Rev Pharmacoecon Outcomes Res 2022;22(2):177-195.
Doose A, Hellerhoff I, Tam FI, King JA, Seidel M, Geisler D, et al. Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. Psychoneuroendocrinology 2022;135.
Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis 2022;13.
Koeditz D, Frensch J, Bierbaum M, Ness N-, Ettle B, Vudumula U, et al. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Mult Scler J Exp Transl Clin 2022;8(1).
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, et al. Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. Ther Adv Neurol Disord 2022;15.
Ziemssen T, Smolinski L, Członkowska A, Akgun K, Antos A, Bembenek J, et al. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease. Acta Neurol Belg 2022.
